[go: up one dir, main page]

BR0009524A - Uso de um composto, e, composição farmacêutica ou veterinaria - Google Patents

Uso de um composto, e, composição farmacêutica ou veterinaria

Info

Publication number
BR0009524A
BR0009524A BR0009524-9A BR0009524A BR0009524A BR 0009524 A BR0009524 A BR 0009524A BR 0009524 A BR0009524 A BR 0009524A BR 0009524 A BR0009524 A BR 0009524A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical
veterinary composition
formula
neurological
Prior art date
Application number
BR0009524-9A
Other languages
English (en)
Inventor
Gregory Lynn Willis
Original Assignee
Clarencew Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/285,859 external-priority patent/US6310085B1/en
Application filed by Clarencew Pty Ltd filed Critical Clarencew Pty Ltd
Publication of BR0009524A publication Critical patent/BR0009524A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Disabilities (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Social Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

"USO DE UM COMPOSTO, E, COMPOSIçãO FARMACêUTICA OU VETERINARIA". Um método para o tratamento e/ou profilaxia de um distúrbio neurológico ou neuropsiquiátrico associado com função de dopamina alterada que compreende a administração de um composto de fórmula (I) ou fórmula (II): a um paciente em necessidade do mesmo.
BR0009524-9A 1996-10-04 2000-03-31 Uso de um composto, e, composição farmacêutica ou veterinaria BR0009524A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO2745A AUPO274596A0 (en) 1996-10-04 1996-10-04 Method for the treatment of neurological or neuropsychiatric disorders
US09/285,859 US6310085B1 (en) 1997-10-03 1999-04-02 Method for the treatment of neurological or neuropsychiatric disorders
PCT/AU2000/000275 WO2000059504A1 (en) 1996-10-04 2000-03-31 Method for the treatment of neurological or neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
BR0009524A true BR0009524A (pt) 2002-02-19

Family

ID=37945448

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009524-9A BR0009524A (pt) 1996-10-04 2000-03-31 Uso de um composto, e, composição farmacêutica ou veterinaria

Country Status (21)

Country Link
US (1) US20020068692A1 (pt)
EP (2) EP0964679A4 (pt)
JP (2) JP2001503394A (pt)
CN (1) CN1345238A (pt)
AU (3) AUPO274596A0 (pt)
BG (1) BG106065A (pt)
BR (1) BR0009524A (pt)
CA (2) CA2267381A1 (pt)
CZ (1) CZ20013487A3 (pt)
EE (1) EE200100511A (pt)
HU (1) HUP0200287A3 (pt)
IL (1) IL145696A0 (pt)
MA (1) MA25404A1 (pt)
MX (1) MXPA01009963A (pt)
NO (1) NO20014674D0 (pt)
NZ (1) NZ515023A (pt)
PL (1) PL350961A1 (pt)
SK (1) SK13862001A3 (pt)
TR (1) TR200102864T2 (pt)
WO (2) WO1998015267A1 (pt)
ZA (1) ZA200108592B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US7303869B2 (en) 2001-07-17 2007-12-04 Northwestern University Solid-phase reactions
US7485443B2 (en) 2001-07-17 2009-02-03 Northwestern University Solid-phase reactions
JP2005219511A (ja) * 2002-02-05 2005-08-18 Azumaya:Kk ハイジャク防止システムおよぴ防止方法
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US9827210B2 (en) * 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
EP2701707B1 (en) * 2011-04-29 2020-09-02 Rutgers, the State University of New Jersey Method of treating dyskinesia
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
JP6555884B2 (ja) 2011-05-31 2019-08-07 クラレンシュウ・プロプライエタリー・リミテッド 運動に関連する神経障害を予防および治療する方法
GB201416017D0 (en) 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
CN116354924B (zh) * 2021-12-27 2025-05-30 江苏恩华药业股份有限公司 一种2-咪唑酮衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH05500166A (ja) * 1989-09-15 1993-01-21 ドネツキ　ゴスダルストベンニ　メディツィンスキ　インスティテュト　イメニ　エム．ゴルコゴ 個体の感情状態を矯正するための装置
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5046494A (en) * 1990-08-27 1991-09-10 John Searfoss Phototherapy method
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB2282807A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Tryptophan esters and amides as tachykinin receptor antagonists
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP0964679A1 (en) 1999-12-22
TR200102864T2 (tr) 2002-03-21
HUP0200287A3 (en) 2002-12-28
PL350961A1 (en) 2003-02-24
EP1189613A1 (en) 2002-03-27
WO1998015267A1 (en) 1998-04-16
NO20014674L (no) 2001-09-26
US20020068692A1 (en) 2002-06-06
CZ20013487A3 (cs) 2003-04-16
IL145696A0 (en) 2002-06-30
WO2000059504A1 (en) 2000-10-12
CA2267381A1 (en) 1998-04-16
NZ515023A (en) 2004-01-30
AU4372597A (en) 1998-05-05
AU782492B2 (en) 2005-08-04
CN1345238A (zh) 2002-04-17
EP0964679A4 (en) 2002-09-11
JP2002541105A (ja) 2002-12-03
EE200100511A (et) 2002-12-16
JP2001503394A (ja) 2001-03-13
AUPO274596A0 (en) 1996-10-31
MXPA01009963A (es) 2003-07-14
NO20014674D0 (no) 2001-09-26
SK13862001A3 (sk) 2003-04-01
AU3410200A (en) 2000-10-23
CA2366850A1 (en) 2000-10-12
MA25404A1 (fr) 2002-04-01
ZA200108592B (en) 2002-10-18
BG106065A (en) 2002-04-30
EP1189613A4 (en) 2004-02-11
HUP0200287A2 (en) 2002-06-29
AU736005B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BG101118A (en) Therapeutical compounds
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
NO931766D0 (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
UA41355C2 (uk) Засіб для лікування нейро-сніду
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
FI944770A0 (fi) Neurotensiiniin vaikuttavia substituoituja 1-naftyylipyratsoli-3-karboksiamideja, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ES2157107T3 (es) Uso de moxonidina para el tratamiento del dolor neuropatico.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
BR9713087A (pt) Composição farmacêutica estabilizada, utilização e processo para preparar a mesma, e, utilização de ácido metanossulfÈnico ou ácido clorìdrico
BG101325A (en) Use of muramyl peptide compounds
BR0314555A (pt) Derivados de epotilona para o tratamento de mieloma múltiplo
IL108283A0 (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.